<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752087</url>
  </required_header>
  <id_info>
    <org_study_id>16489</org_study_id>
    <secondary_id>I8B-MC-ITRP</secondary_id>
    <nct_id>NCT02752087</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants</brief_title>
  <official_title>A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY900014 Test Versus Reference Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study of healthy participants will evaluate the concentration of a test LY900014 and a
      reference LY900014 formulation in the bloodstream and how it affects the blood sugar levels.
      The whole study, including screening, will take up to 8 weeks to complete.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under The Concentration Curve (AUC) of LY900014</measure>
    <time_frame>Predose through 8 hours post dose administration for each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Predose through 8 hours post dose for each treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY900014 Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900014 test dose administered via subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014 Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LY900014 reference dose administered via SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900014 Test</arm_group_label>
    <arm_group_label>LY900014 Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants who can potentially get pregnant:

               -  Must have a negative pregnancy test at the time of screening

               -  Agree to continue to use a reliable method of birth control until the end of the
                  study

          -  Have a body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/mÂ²),
             inclusive, at screening

          -  Are nonsmokers, have not smoked for at least 2 months before entering the study

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or any
             other type of medical research judged not to be scientifically or medically compatible
             with this study

          -  Have known allergies to insulin lispro, related compounds, or any components of the
             formulation

          -  Have significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs

          -  Intend to use over-the-counter or prescription medication within 7 and 14 days,
             respectively, before dosing (apart from vitamin/mineral supplements, occasional
             paracetamol, hormonal contraception, or thyroid-replacement therapy)

          -  Have used systemic glucocorticoids within 3 months prior to entry into the study

          -  Have donated blood of more than 450 milliliters (mL) or more in the last 3 months or
             provided any blood donation within the last month before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

